Heading 1
Heading 2
Heading 3
Heading 4
This is Signal by Foresight, the weekly chemical regulation newsletter dedicated to giving you everything you need to know in a 5-minute read or less. You are receiving this email because you registered for a recent webinar.
- This is a test
- This is a test
- This is a test
- This is a test
- This is a test
- This is a test
🔍 The Headlines in Focus
🚨 35% of Safety Data Sheets Found Non-Compliant
REF-11 report shows 35% of safety data sheets fail to meet EU standards, highlighting major deficiencies like missing nanoform details (67%) and data inaccuracies (27%). Recommendations include improved practices and awareness campaigns to address gaps.
Read the full article
🧪 EPA Draft Flags 1,3-Butadiene as a Health Hazard
The EPA’s draft evaluation identifies 1,3-butadiene as a significant health risk, particularly for workers and nearby communities. Key risks include blood disorders and leukaemia. Public comments are open until February 2025.
Read the full article
🔍 EPA Calls for Peer Reviewers on Phthalates Risk
The EPA seeks experts to review risk evaluations for phthalates linked to male reproductive health issues. Nominations close 30 days from the Federal Register notice. Findings will shape regulatory decisions.
Read the full article
🌍 New Rules Proposed for Fluoroalkyl Compounds
The EPA has proposed SNUR updates for 17 substances, mandating risk assessments for new uses. The rules align with efforts to regulate PFAS, aiming to reduce their environmental and health impacts. Public comments close 30 December 2024.
Read the full article
🐟 Belgium Finalises Climbazole Evaluation
Belgium confirms climbazole as an environmental endocrine disruptor with significant aquatic toxicity. No consumer risks at current cosmetic use levels were found. Regulatory updates are expected by 2025.
Read the full article
